AbbVie Receives Health Canada Approval of ORILISSA (elagolix) for the Treatment of Moderate to Severe Pain Associated with Endometriosis
- Endometriosis affects up to one in 10 women of reproductive age in Canada.1
- 7 out of 10 women being managed for endometriosis have unresolved pain throughout the month.2
- The approval of ORILISSA is supported by data from two replicate Phase 3 studies, which evaluated nearly 1,700 women.
- In clinical trials, ORILISSA demonstrated sustained relief over 12 months across the two most common types of pain: dysmenorrhea and non-menstrual pelvic pain.3
Canadian women prescribed ORILISSA will have the opportunity to be enrolled in AbbVie Care, AbbVie's signature care program. The program is designed to provide a wide range of customized services including reimbursement and financial support, pharmacy services, lab work reminders and coordination, personalized education and ongoing disease management support throughout the treatment and beyond. For more information, please visit www.abbviecare.ca. About AbbVie
AbbVie is a global, research and development-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world's most complex and critical conditions. The company's mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience.? In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us at www.abbvie.ca?and www.abbvie.com. Follow @abbvieCanada?and @abbvie on Twitter or view careers on our?Facebook?or?LinkedIn?page. About Neurocrine Biosciences, Inc.
Neurocrine Biosciences, a San Diego based biopharmaceutical company, is focused on developing treatments for neurological and endocrine related disorders. The company discovered, developed and markets INGREZZA? (valbenazine), the first FDA approved product indicated for the treatment of adults with tardive dyskinesia, a movement disorder. Discovered and developed through Phase II clinical trials by Neurocrine, ORILISSA? (elagolix), the first FDA-approved oral medication for the management of endometriosis with associated moderate to severe pain in over a decade, is marketed by AbbVie as part of a collaboration to develop and commercialize elagolix for women's health. Neurocrine's clinical development programs include opicapone as an adjunctive therapy to levodopa/DOPA decarboxylase inhibitors in Parkinson's disease patients, elagolix for uterine fibroids with AbbVie, valbenazine for the treatment of Tourette syndrome, and NBI-74788 for the treatment of congenital adrenal hyperplasia (CAH). For more information and the latest updates from Neurocrine, please visit www.neurocrine.com.